Strategy& Insider

Strategy& Insider

Exploring future trends and their impacts

Strategy& Insider Episode 47 - Unlocking personalized health through genomics

Download it: MP3 | AAC | OGG | OPUS
Read transcript

In this episode, Michel Mommejat, President of A.D.A.M. Innovations, shares how genomics and AI are transforming healthcare from reactive treatment to preventative wellcare. Recorded in Tokyo, this conversation explores what your DNA can reveal as a biological blueprint, why Japan serves as the world's laboratory for healthy aging, and how combining genetic data with biomarkers and lifestyle information creates a dynamic, personalized health ecosystem. Michel also discusses the ethical frameworks needed to protect the most sensitive data that exists, the concept of Artificial General Gene Intelligence, and practical applications like pharmacogenomics that are already changing how we think about medication. Tune in for a visionary conversation on the future of health and longevity.


Comments


New comment

Your name or nickname, will be shown publicly
At least 10 characters long
By submitting your comment you agree that the content of the field "Name or nickname" will be stored and shown publicly next to your comment. Using your real name is optional.

About this podcast

The Strategy& Insider podcast aims to explore some of the most critical future trends and their impacts. Strategy& talks to industry experts and leading practitioners from different sectors. The conversations will make you more familiar with key developments by providing you with insights that really matter.

The first season will tackle some of the most fundamental questions in the healthcare industry. While technology has quickly transformed how we shop, bank, and travel, it yet has to impact on how we receive healthcare. The adoption of digitally enabled tools for diagnostics, treatment, and management, for example, has been rather modest - especially compared to what is already possible.

Together with experts across all sectors including pharma executives, leading academics and practitioners at hospitals we will discuss how the healthcare industry is expected to change.

by Thomas Solbach, Ghioia Irritier, Jan-Philipp Loch

Subscribe

Follow us